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A B S T R A C T
The involvement of the 18kDa translocator protein (TSPO), a marker of neuroinflammation, in Alzheimer's disease (AD) remains controversial. In the present report, we used [
125 I]-CLINDE, a SPECT TSPO radiotracer never before used in AD, and we investigated the relationship between TSPO and amyloid plaque density (using [ 125 I]-DRM106) in a triple transgenic mouse model of AD (3xTgAD, APP SWE , PS1 M146V and Tau P301L ). Our results
show that TSPO increases appear before those of amyloid deposits. Moreover, the different parts of the hippocampus are differentially affected. Indeed, for both TSPO and amyloid, the subiculum is affected earlier and the ventral hippocampus later than the dorsal hippocampus. In the subiculum and the dorsal hippocampus of 3xTgAD mice, a positive correlation between TSPO and of amyloid deposit levels is observed. This data supports the hypothesis that TSPO could be used as a predictive marker of amyloid pathology. In addition, our immunohistochemical data shows a segregation of TSPO in the hippocampus and immunofluorescence imaging revealed a mainly microglial origin of the TSPO expression. Thus, imaging TSPO with CLINDE may be a good alternative to PET radiotracers.
Introduction
Alzheimer's disease (AD), the most common neurodegenerative disorder, is characterized by two neuropathological hallmark-lesions, the extracellular deposits of amyloid β (Aβ) and intracellular neurofibrillary tangles (NFT), formed by hyperphosphorylated tau proteins (PTau). Neuroinflammatory processes are also involved in the pathophysiology of AD even if their precise role with respect to the evolution of the pathology is debated (Calsolaro and Edison, 2016). Brain glial activation induces the overexpression of the 18kDa translocator protein (TSPO), which is therefore used as a neuroinflammatory marker. Several radiotracers were developed for in vivo imaging of TSPO by positron emission tomography (PET) or single-photon emission computed tomography (SPECT). In the field of AD research, some studies reported an increase in TSPO densities (Cagnin et al., 2001; Edison et al., 2008; Fan et al., 2015; Hamelin et al., 2016; Kreisl et al., 2013; Lyoo et al., 2015; Schuitemaker et al., 2013; Varrone et al., 2015; Versijpt et al., 2003) while others showed no effects (Golla et al., 2015; Gulyas et al., 2011; Schuitemaker et al., 2013; Varrone et al., 2013; Wiley et al., 2009) . For a proper comparison of these clinical studies, it is important to highlight several methodological concerns. Some of these researches included participants with probable AD but medication, notably acetylcholinesterase inhibitors, which interfere with inflammatory pathways (Pohanka, 2014), was not always taken into account; measurement of the rs6971 TSPO polymorphism, which affects binding of highaffinity radiotracers (Owen et al., 2011) was not systematic, and, considerable age variability was observed between studies or in some cases between control and AD groups, which may be a confounding factor,
